Purple Biotech Ltd (1YI1) Trades

North Bay Resources has reached a key milestone in its gold production efforts, successfully completing a test shipment of 327 lbs. of gold concentrate from the Bishop Gold Mill to Just Refiners in Reno, NV. CEO Jared Lazerson shared the update with Steve Darling from Proactive, emphasizing the company’s progress in optimizing mill operations and enhancing gold recovery from its Fran Gold Property. The February ore processing runs yielded approximately 2.44 troy ounces of contained gold from 10 tons of ore, equating to a recovered gold grade of 0.24 ounces per ton. Additionally, 0.1 ounces of contained gold remains in low-grade concentrate at the mill. Current estimates place overall recovery at 50%, with gravity-recoverable gold recovery at 70%. Metallurgical testing suggests that up to 67% gravity recovery can be achieved, with an additional 30% recoverable through flotation. To further enhance recovery rates, North Bay Resources is bringing its flotation circuit online, targeting very fine gold and gold in quartz that is not efficiently captured by existing gravity separation methods. This upgrade is expected to boost overall gold recovery by up to 30% as the company continues to refine its extraction process. With ongoing improvements to both its gravity and flotation circuits, North Bay Resources is poised to significantly enhance gold recovery and production efficiency at the Bishop Gold Mill, marking an important step in its broader operational strategy. #proactiveinvestors #northbayresourcesinc #otc #nbri #PlatinumConcentrate #NorthBayResources #MiningNews #CaliforniaGold #JaredLazerson #GoldRush #ProactiveInvestors #PreciousMetals #MiningUpdates ---#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Helium One Global Ltd (AIM:HE1, OTCQB:HLOGF) CEO Lorna Blaisse talked with Proactive's Stephen Gunnion about the latest developments for the company, including a major milestone in Tanzania and updates on its US drilling campaign. Blaisse discussed receiving an offer letter for a mining licence in Tanzania, highlighting its significance as the first of its kind for helium and its larger-than-standard 480 km² coverage. She explained that this will allow Helium One to further appraise the subsurface structure following its Itumbula discovery. The company is currently reviewing the terms, including regulatory requirements and partnerships with the Tanzanian government. On the US front, Blaisse provided updates on the Jackson-31 well in Colorado, confirming free-flowing helium gas with no water association—an important distinction from the Tanzanian project. The rig is now mobilising to drill Jackson-4, part of a broader development campaign that will see multiple wells drilled in the coming weeks. Blaisse also reaffirmed that Blue Star remains on track for helium production in the first half of 2025. With active projects in both Tanzania and the US, Helium One is progressing toward becoming a key helium producer. 📢 For more updates, visit Proactive’s YouTube channel. Don’t forget to like, subscribe, and turn on notifications! #HeliumOne #MiningLicense #HeliumExploration #EnergyNews #Tanzania #Colorado #NaturalGas #Investing #ProactiveInvestors

BioHarvest Sciences has announced a significant advancement in liver health research, with new in vitro test results demonstrating the efficacy of its proprietary Olive Cell compound in reducing fat accumulation in human liver cells. CEO Ilan Sobel shared the news with Steve Darling from Proactive, highlighting the compound’s potential in addressing non-alcoholic fatty liver disease (NAFLD)—a condition that affects 30–40% of U.S. adults and currently has limited FDA-approved treatment options. The latest studies revealed that the Olive Cell compound mitigated fat accumulation in both a liver steatosis model and experimental models of liver fibrosis. Additionally, it reduced collagen type 1 levels in XL-2 cells, a key marker of fibrosis progression, further reinforcing its therapeutic potential. BioHarvest attributes these promising results to the compound’s high levels of Verbascoside, a bioactive polyphenol with anti-inflammatory and antioxidant properties. Looking ahead, the company plans to conduct further studies in 2025, with the goal of launching Olive Cell as a nutraceutical product in 2026. Meanwhile, BioHarvest is also exploring pharmaceutical partnerships to bring the compound to market through a CDMO (Contract Development and Manufacturing Organization) model. With these groundbreaking findings, BioHarvest Sciences is positioning itself at the forefront of liver health innovation, offering a potential new solution for millions affected by NAFLD and liver fibrosis. #proactivinvestors #nasdaq #bhst #pharma #biotech #hearthealth #fattyliverdisease #BioHarvestSciences, #IlanSobel, #RevenueGrowth, #NasdaqListing, #IlanSobel #VINIA #HealthTech #Biotech LiverHealth #OliveCell #Verbascoside #NonAlcoholicFattyLiver #SupplementScience #HealthInnovation

Race Oncology Ltd CEO and managing director Daniel Tillett talked with Proactive about the company’s development of a reformulated cancer drug aimed at improving chemotherapy treatment. Tillett discussed the challenges of chemotherapy, including severe side effects, and how Race Oncology is working to minimise these risks while enhancing treatment effectiveness. He explained that the company has taken an older, previously approved drug and developed a new formulation that improves its delivery while protecting patients from heart-related side effects. This new approach, which involves combining the reformulated drug with anthracyclines, aims to enhance cancer treatment while reducing long-term health risks for patients. Tillett highlighted the significant market potential for the company’s drug, given that anthracyclines remain a cornerstone of cancer treatment. The company is now advancing into clinical trials, with results expected to provide key insights into the drug’s effectiveness in humans. Watch the full interview to learn more about Race Oncology’s latest advancements. Don’t forget to like this video, subscribe to Proactive’s YouTube channel, and turn on notifications for more updates on cutting-edge biotech developments. #RaceOncology #CancerTreatment #Biotech #Chemotherapy #Pharmaceuticals #DrugDevelopment #ClinicalTrials #OncologyResearch #Investing #CancerResearch #Cardioprotection